572 related articles for article (PubMed ID: 23890557)
1. Vitamin D in thyroid tumorigenesis and development.
Clinckspoor I; Verlinden L; Mathieu C; Bouillon R; Verstuyf A; Decallonne B
Prog Histochem Cytochem; 2013 Aug; 48(2):65-98. PubMed ID: 23890557
[TBL] [Abstract][Full Text] [Related]
2. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
3. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
4. 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Clinckspoor I; Verlinden L; Overbergh L; Korch C; Bouillon R; Mathieu C; Verstuyf A; Decallonne B
J Steroid Biochem Mol Biol; 2011 Mar; 124(1-2):1-9. PubMed ID: 21182945
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors.
Clinckspoor I; Hauben E; Verlinden L; Van den Bruel A; Vanwalleghem L; Vander Poorten V; Delaere P; Mathieu C; Verstuyf A; Decallonne B
J Histochem Cytochem; 2012 Jul; 60(7):502-11. PubMed ID: 22511602
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
7. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells.
Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D in normal and pathological parathyroid glands: new prospects for treating hyperparathyroidism (review).
Buchwald PC; Westin G; Akerström G
Int J Mol Med; 2005 Apr; 15(4):701-6. PubMed ID: 15754035
[TBL] [Abstract][Full Text] [Related]
9. The anti-cancer actions of vitamin D.
Chiang KC; Chen TC
Anticancer Agents Med Chem; 2013 Jan; 13(1):126-39. PubMed ID: 23094926
[TBL] [Abstract][Full Text] [Related]
10. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands.
Jurutka PW; Bartik L; Whitfield GK; Mathern DR; Barthel TK; Gurevich M; Hsieh JC; Kaczmarska M; Haussler CA; Haussler MR
J Bone Miner Res; 2007 Dec; 22 Suppl 2():V2-10. PubMed ID: 18290715
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
13. Selection of High-Quality Spermatozoa May Be Promoted by Activated Vitamin D in the Woman.
Bøllehuus Hansen L; Rehfeld A; de Neergaard R; Nielsen JE; Iversen LH; Boisen IM; Mortensen LJ; Lanske B; Almstrup K; Carlsen E; Berg AH; Jørgensen N; Andersen AN; Juul A; Blomberg Jensen M
J Clin Endocrinol Metab; 2017 Mar; 102(3):950-961. PubMed ID: 27977320
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells.
Capiati DA; Rossi AM; Picotto G; Benassati S; Boland RL
J Cell Biochem; 2004 Oct; 93(2):384-97. PubMed ID: 15368364
[TBL] [Abstract][Full Text] [Related]
15. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
16. 1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action.
Nezbedova P; Brtko J
Endocr Regul; 2004 Mar; 38(1):29-38. PubMed ID: 15147236
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.
Ono Y
J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874
[TBL] [Abstract][Full Text] [Related]
20. Genomic mechanisms controlling renal vitamin D metabolism.
Meyer MB; Pike JW
J Steroid Biochem Mol Biol; 2023 Apr; 228():106252. PubMed ID: 36657729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
